Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
AstraZeneca Withdraws Iressa Accelerated Approval NDA; Rules out Refiling with PGx Data
February 09, 2011
Although the decision to withdraw its accelerated approval NDA doesn't preclude the company from filing an entirely new NDA for Iressa in NSCLC patients with EGFR mutations, as it has done in several European countries, AstraZeneca has decided not to try to relaunch Iressa with a PGx strategy in the US.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- ODAC Meeting on Accelerated Approval for Oncologics Raises Questions about Strategies for PGx Drugs
February 16, 2011 / Pharmacogenomics Reporter - Despite PGx Leads, Avastin Access Debate Not Focused on Personalized Medicine Strategies
August 25, 2010 / Pharmacogenomics Reporter - UK's NICE Backs Iressa Coverage at Fixed Price; NHS Pays for Genetic Testing
June 2, 2010 / Pharmacogenomics Reporter - Clovis, Avila to Co-develop Targeted NSCLC Drug with Companion Test in Deal Worth up to $209M
May 26, 2010 / Pharmacogenomics Reporter - UK's NICE Cites Lack of Response Markers for BMS' Yervoy as Factor in Negative Recommendation
October 19, 2011 / Pharmacogenomics Reporter